Welcome to our dedicated page for Beam Therapeutics news (Ticker: BEAM), a resource for investors and traders seeking the latest updates and insights on Beam Therapeutics stock.
Beam Therapeutics Inc. (Nasdaq: BEAM) is a pioneering biotechnology company at the forefront of developing precision genetic medicines through its innovative base editing technology. Co-founded by some of the leading figures in the field of CRISPR gene editing, Beam Therapeutics aims to provide life-long cures for patients suffering from severe diseases by repairing disease-causing point mutations, introducing protective genetic variations, or modulating gene expression.
The company’s core technology, base editing, involves making precise, targeted changes to single DNA bases without causing double-stranded breaks. This method sets Beam apart and offers significant potential in creating a wide array of therapeutic strategies.
Beam's robust pipeline includes several promising programs such as BEAM-101 for sickle cell disease, BEAM-301 for glycogen storage disease type Ia, BEAM-302 for alpha-1 antitrypsin deficiency, and BEAM-201 targeting T-cell acute lymphoblastic leukemia (T-ALL). These programs highlight Beam’s commitment to addressing unmet medical needs through innovative solutions.
One of the company's notable recent achievements includes a strategic partnership with Eli Lilly, which involves a $250 million upfront payment and regulatory milestone payments that could total up to $600 million. This collaboration aims to enhance Beam's cash position and extend its operational runway to the second half of 2026.
Beam Therapeutics has also made significant strides in its internal capabilities by establishing a Good Manufacturing Practice (GMP) facility, ensuring high-quality production of their genetic therapies.
Financially, Beam is well-positioned, with substantial cash reserves expected to fund its operations and capital needs into 2027. The company is focused on advancing its clinical trials and research programs efficiently, in alignment with its strategic business priorities.
Beam Therapeutics continues to explore collaborative opportunities and partnerships to expand the reach of its base editing technology. The company remains dedicated to its mission of transforming the lives of patients through groundbreaking genetic medicines.
Beam Therapeutics (Nasdaq: BEAM) announced promising preclinical data at the 2021 International HBV Meeting regarding its cytosine base editors (CBEs) targeting hepatitis B virus (HBV). The study demonstrated significant reductions in viral markers, including HBsAg, utilizing multiplexing techniques. Results indicated a 30%-60% editing efficiency of cccDNA without reducing its levels, and a 20% enhanced efficacy when combined with standard antiviral treatment. Beam plans to advance its base editing approach to in vivo proof of concept models, highlighting its potential in treating chronic HBV infection.
Beam Therapeutics (Nasdaq: BEAM) announced new preclinical data on September 23, 2021, showcasing advancements in their lipid nanoparticle (LNP) formulations for in vivo liver editing. Key findings include up to 60% editing potency at 1.0 mg/kg in non-human primates (NHPs) and well-tolerated formulations at doses up to 1.5 mg/kg. The company also highlighted potential applications for delivering base editors beyond the liver to hematopoietic stem and progenitor cells (HSPCs). These developments may support future therapeutic applications for genetic diseases.
Beam Therapeutics (Nasdaq: BEAM) announced its participation in the 2021 Wells Fargo Virtual Healthcare Conference, where CEO John Evans will engage in a fireside chat on Sept. 10, 2021, at 9:20 a.m. ET. The event will be accessible via a live webcast on the company's investor website, with an archive available for 60 days post-event. Beam Therapeutics focuses on precision genetic medicines through its innovative base editing technology, which allows for precise single base changes in DNA without double-stranded breaks, aiming to provide long-term cures for serious diseases.
Beam Therapeutics reported significant progress in its base editing programs, with plans to submit its first IND for BEAM-101 in H2 2021. The company initiated IND-enabling studies for BEAM-201 targeting T-cell acute lymphoblastic leukemia. Financially, Beam's Q2 2021 net loss was $76.3 million, or $1.23 per share, compared to $34.2 million, or $0.69 per share, in Q2 2020. With a cash position of $615.3 million, the company is well-equipped to advance its innovative pipeline, including partnerships to expand therapeutic applications. Upcoming presentations scheduled for August and September 2021 will further highlight their advancements.
Beam Therapeutics (Nasdaq: BEAM) announced that its president and chief scientific officer, Giuseppe Ciaramella, Ph.D., will speak at the 2021 Wedbush PacGrow Healthcare Conference on Aug. 10, 2021, at 9:10 a.m. ET. The panel discussion, titled “So Let it Be (Re)Written - Updates in Gene Modulation,” will be available via a live webcast on the company's investor website and archived for 60 days. Beam Therapeutics specializes in precision genetic medicines through its proprietary base editing technology, allowing precise genomic alterations without DNA breaks.
Beam Therapeutics, a precision genetic medicine company (Nasdaq: BEAM), announced that CEO John Evans will speak at the 2021 William Blair Biotech Focus Conference on July 15, 2021, at 1:00 p.m. ET. The event will feature a live webcast accessible via the company's investor section on their website, with an archive available for 60 days post-event.
Beam specializes in base editing technology, enabling precise genetic alterations without DNA breaks, and is committed to developing lifelong cures for serious diseases.
Beam Therapeutics (Nasdaq: BEAM) has announced that its CEO, John Evans, will participate in a fireside chat at the 2021 Jefferies Virtual Healthcare Conference on June 1, 2021, at 9:30 a.m. ET. The live webcast will be accessible in the investor section of Beam's website and will be archived for 60 days post-event.
Beam specializes in precision genetic medicines through base editing, a technology allowing precise changes to DNA sequences without double-stranded breaks. The company is dedicated to advancing a diversified portfolio of gene editing programs aimed at treating serious diseases.
Beam Therapeutics, a biotechnology company, reported promising advances in its base editing platform and pipeline, with in vivo editing in liver cells of non-human primates reaching 52%. The company is on track to submit its first IND application for BEAM-101 in the second half of 2021. Cash reserves stood at $503.5 million, a significant increase from $253.4 million year-over-year. However, R&D expenses surged to $190.1 million, largely due to the acquisition of Guide Therapeutics, contributing to a net loss of $201.6 million.
Beam Therapeutics (Nasdaq: BEAM) announced the presentation of its base editing data at the upcoming ASGCT Annual Meeting, scheduled for May 11-14, 2021. During this event, Beam will demonstrate advancements in its base editing technology, aimed at treating serious genetic diseases. Key presentations include a workshop on gene editing and a poster session highlighting the use of lipid nanoparticles for delivery. The company is advancing towards filing an IND application for its lead program, BEAM-101, and is working on its first liver development candidate.
Beam Therapeutics (Nasdaq: BEAM) has published research in The CRISPR Journal detailing the development of Inlaid Base Editors (IBEs), enhancing base editing capabilities. This innovation aims to treat sickle cell disease (SCD) by converting the sickle hemoglobin allele to the benign HbG-Makassar variant, achieving over 70% editing efficiency in patient-derived cells. IBEs provide a broader editing range with reduced off-target effects, solidifying Beam's position as a leader in genetic medicine. The company plans to submit its first investigational new drug application in H2 2021.
FAQ
What is the current stock price of Beam Therapeutics (BEAM)?
What is the market cap of Beam Therapeutics (BEAM)?
What is Beam Therapeutics Inc. known for?
What is base editing technology?
What are some of Beam's key pipeline programs?
How is Beam Therapeutics financially positioned?
Who are Beam's collaborative partners?
What recent achievement highlights Beam's progress?
What is the mission of Beam Therapeutics?
What are Beam's plans for 2024?
What makes Beam's base editing technology unique?
What impact does Beam aim to achieve with its therapies?
